Dr Desai on the Efficacy of Divarasib Plus Cetuximab in KRAS G12C–Mutant CRC

Jayesh Desai, MBBS, FRACP, discusses efficacy data for the combination of divarasib plus cetuximab in patients with colorectal cancer harboring a KRAS G12C mutation from a phase 1B study.

Related Keywords

Melbourne ,Victoria ,Australia ,Jayesh Desai ,Sir Peter Maccallum Department Of Oncology ,Peter Maccallum Cancer Centre ,Phasei Early Drug Development Program ,University Of Melbourne ,Clinical Research ,Early Drug Development Program ,Sir Peter Maccallum Department ,Aacr Annual Meeting ,Onclive Tv ,Conference ,